Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (April 2025)
25 slides from Transgene Sa's investor presentation, Apr 23, 2025
Slide 1: Unlocking the Full Potential of the Immune System Against Cancer
Unlocking the Full Potential of the Immune System Against Cancer Investor Presentation April 23, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Transgene in a Snapshot
Transgene in a Snapshot Click to edit Master title style Lead program TG4050 Additional programs Unique and highly to deliver data and R&I activity to potent and create significant deliver news flow and viral vector-based value in early setting fuel Transgene’s immunotherapies solid tumors between p
Slide 4: myvac® – A Novel Individualized Cancer Immunotherapy Platform
myvac® – A Novel Individualized Cancer Immunotherapy Platform Click to edit Master title style MVA VECTOR BENEFITS THE RIGHT NEOANTIGENS INDICATION Induces broad and specific immune Comprises up to 30 neoantigens Targeting head and neck patients – response – Almost all patients treated selected usin
Slide 5: Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors
Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors Click to edit Master title style Product Indication Collaboration Discovery Phase I Phase II LEAD ASSET: INDIVIDUALIZED NEOANTIGEN CANCER VACCINES (myvac® platform) 24-month follow-up for all patients Head and neck recruited in
Slide 6: Neoantigen Therapeutic Cancer Vaccine
Neoantigen Therapeutic Cancer Vaccine Focused on delivering the promise of individualized cancer vaccine
Slide 7: myvac® - TG4050 | Combines Unique Know How and Expertise
myvac® - TG4050 | Combines Unique Know How and Expertise Click to edit Master title style MVA viral vector: a powerful Clinically-validated Artificial Intelligence & platform for vaccine development Bioinformatics powered approach Neoantigen identification Strongly immunogenic vector • Based on mult
Slide 8: TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy
TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy Click to edit Master title style Need to prevent or delay relapse Phase I/II trial design Approx. 80 patients With currently approved treatments, with locoregionally advanced HPV-negative approx. 25% patients relapse S
Slide 9: TG4050 | Promising Signals of Clinical Activity in Adjuvant Setting
TG4050 | Promising Signals of Clinical Activity in Adjuvant Setting Click to edit Master title style No related SAEs Head & Neck Cancer Trial Good safety profile 32 patients randomized – September 2024 Median follow-up of 24.1 months 6 months 12 months 18 months 24 months 30 months 36 months 42 mont
Slide 10: TG4050 | Generates and/or Expands Tumor Specific T Cells
TG4050 | Generates and/or Expands Tumor Specific T Cells Click to edit Master title style Number of positive responses per patient (Elispot assay) Head and Neck Cancer (Phase I part) Despite low mutational burden, De novo responses Amplified responses immunogenic targets could be selected Stable res
Slide 11: TG4050 | Persistent Specific Cellular Response Following Vaccination
TG4050 | Persistent Specific Cellular Response Following Vaccination Click to edit Master title style Patients displayed sustained neoantigen-specific CD8+ responses against multiple selected targets over 7 months Induction period Boost period Source: G. Le Tourneau et al., “Randomized Phase I Trial
Slide 12: TG4050 | Potential to Extend Remission Period and Address Significant Medical Need
TG4050 | Potential to Extend Remission Period and Address Significant Medical Need Click to edit Master title style Head & Neck program one patient • one genome • one vaccine Phase I part – 24-month follow up to be presented at ASCO (June 1st, 2025) Signs Excellent Ongoing Phase II part – Last patie
Slide 13: Other viral vector-based assets
Other viral vector-based assets Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors
Slide 14: TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer
TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer Click to edit Master title style Randomized Phase II trial in patients with HPV16+ cervical Top line data and anogenital cancer (n=90) incl. cervical, vulvar, vaginal, penile and anal cancers NCT: 03260023 • Primary objec
Slide 15: Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation
Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Click to edit Master Data Support Intravenous (IV) Route of Administration title style Patented Backbone VVcopTK-RR- vector with multiple Cancer cell death through multiple MOAs competitive ad
Slide 16: BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF
BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF Completed Phase Click to edit Master I/IIa Trial Assessing IT Route of Administration title style The right virus + payload Promising antitumor activity* monotherapy and combination w. anti-PD1 VVcopTK-RR- oncolytic armed
Slide 17: TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor
TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor Ongoing Click to edit Phase I Trial Master title style to Assess Systemic Route of Administration Oncolytic armed with IL-12 and anti-CTLA4 Ab • Triggers a powerful antitumor immune response • Restores the immune defenses w
Slide 18: Outlook
Outlook transgene
Slide 19: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Click to edit Master title style Business funded Enables Transgene to deliver significant milestones with myvac® platform and other until the end of April 2026 viral vector-based immunotherapies | Neoantigen vaccine − TG4050 Other viral
Slide 20: Appendices
Ccremecrane Appendices
Slide 21: New Leadership to Take Transgene to the Next Level
New Leadership to Take Transgene to the Next Level Click to edit Master title style ALESSANDRO RIVA, MD MAURIZIO CEPPI, PhD EMMANUELLE DOCHY, MD VP, Medical Affairs, Chief Chairman & CEO VP, Chief Scientific Officer Medical Officer 30+ years experience LUCIE LARGUIER JAMES WENTWORTH VP, Chief Financ
Slide 22: Environmental, Social and Governance Commitments
Environmental, Social and Governance Commitments Click to edit Master title style 44/100 Vigeo Eiris Transgene’s ESG strategy is 85/100 (+20 pts) based on 6 commitments Gaïa EthiFinance Award (+8 pts) To patients 99/100 Equal Employment TOP 5 French companies Index To our partners with the best ESG
Slide 23: TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation STANDARD DATA PROCESSING, ROUTINE GENE/EXOME ARTIFICIAL GMP TREATMENT TUMOR BIOPSY SEQUENCING INTELLIGENCE GENE EDITING MANUFACTURING ADMINIS
Slide 24: Exploration of Tumor TME
Exploration of Tumor TME Challenging population with high prevalence of low/negative TME: tumor micro-environment, TMB: tumor mutational burden, PD-L1 expressors and relatively poor pro-immune infiltrates F:Click to edit fibrotic, Master title style NF: non-fibrotic Arm A: TG4050 single agent Arm B:
Slide 25: Contact
C O N TA C T Lucie Larguier Chief Financial Officer investorrelations@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr 25